

New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

- Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life
- Findings demonstrate TriClip™ transcatheter edge-to-edge (TEER) repair is effective at reducing tricuspid regurgitation across a broad range of anatomies
- One-year outcomes for Navitor™ transcatheter aortic valve implantation (TAVI) system show the safety and effectiveness of this therapy and durable performance of the sealing cuff in minimizing paravalvular leak for patients with severe aortic stenosis

ABBOTT PARK, Ill., May 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip™, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor™, the company's latest-generation transcatheter aortic valve implantation (TAVI) system. The company also showcased new data for MitraClip™ and Amplatzer™ Amulet™, two key components of the company's industry-leading structural heart portfolio.

All data were presented at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions, held in Paris from May 17-20, 2022.

30-Day Results from the TriClip bRIGHT Study

New real-world outcomes highlighted in a late-breaking data presentation showed that the TriClip and TriClip G4 transcatheter edge-to-edge repair (TEER) systems significantly reduce tricuspid regurgitation (TR) and substantially improve quality of life across a wide range of anatomically diverse patients, with data through 30 days showing:

- High implant success rate (98%)
- Significant TR reduction (71% moderate or less compared to 3% as baseline) with a strong safety profile (99% freedom from major adverse events)
- Life-changing clinical improvements including 78% of patients achieving New York Heart Association (NYHA) Functional Class I/II (a classification of functional limitations resulting from cardiac disease), an improvement by 57% from baseline of 21%, and an 18-point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (a self-assessment of social abilities, symptoms and quality of life)

"Historically, people suffering from severe tricuspid regurgitation had extremely limited treatment options despite being very ill. Many were ineligible for surgery and were limited to symptom management," said Philipp Lurz, M.D., Ph.D., professor and deputy head of cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. "The late-breaking data show a high rate of implant success and significant reduction in regurgitation. Transcatheter edge-to-edge repair using TriClip has a huge potential to improve patients' quality of life and has entered the clinical stage with widespread use in Europe."

One-Year Results from Study on the Next-Generation Navitor TAVI System

Data from the multi-center, international, single arm study of the Navitor TAVI system with an active sealing cuff to minimize paravalvular leak (PVL) demonstrated improved one-year outcomes for patients with severe, symptomatic aortic stenosis who were at high or extreme surgical risk. Key findings include:

- High procedural success rate of 97.5%
- High rate of no/trace PVL (70.2%) and low rate of mild PVL (28.8%) through one year, indicating the active sealing cuff is effective in mitigating PVL
- Low rate of all-cause mortality (4.2%) at one year
- Single-digit gradients (average 7.5 mmHg) through one year

"Patients with symptomatic, severe aortic stenosis are often at high risk of complications from open-heart surgery due to their old age, frailty or having multiple other diseases and conditions," said Dave Smith, M.D, professor and consultant cardiologist, Morriston Hospital, Swansea, Wales. "The one-year results from the study demonstrate that a minimally invasive TAVI procedure with a Navitor valve offers a safe and effective treatment option for these patients."

Other data sets presented at EuroPCR included positive findings from the EXPAND study which showed MitraClip therapy in heart failure patients with mitral regurgitation experience improved symptoms and quality of life. Additionally, although women have higher rates of early complications with LAA closure than men, results from the Amulet IDE trial found that both women and men implanted with Abbott's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder experienced similar long-term benefits from LAA closure.

"At Abbott, we're dedicated to delivering innovative technologies to help people with debilitating heart conditions live better lives through better health," said Michael Dale, senior vice president of Abbott's structural heart business. "The data presented during this year's EuroPCR meeting underscore our unwavering commitment to providing structural heart solutions, supported by clinical evidence, that surpass existing standards of care."

The TriClip Transcatheter Tricuspid Valve Repair System and Navitor Transcatheter Aortic Valve are approved for investigational use only in the U.S.

For U.S. important safety information on MitraClip, visit <http://abbo.tt/MitraClipG4ISl>.

For U.S. important safety information on the Amplatzer Amulet LAA Occluder, visit <https://abbo.tt/AmuletISl>.


About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott/, on Facebook at www.facebook.com/Abbott and on Twitter [@AbbottNews](https://twitter.com/AbbottNews).

SOURCE Abbott

For further information: Abbott Media, Cynthia Kong (669) 400-6879; Abbott Financial, Mike Comilla (224) 668-1872

Additional assets available online:  [Photos](#) 